Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (1248)	8/12/1999 6:54:00 AM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

In light of the recent merger & acquisition activity in the sector, the following excerpt from an August 8th post from “Mike” on the Yahoo MOGN BB is noteworthy: “I find it interesting that we are doing so many things with PNU. Timothy Rothwell, VP and President of Pharmaceutical Operations at PNU is on our BOD. PNU is our Salagen distributor in Canada. We are doing a PI trial with MGI-114 and PNU's CPT-11. Lastly, we will be co-promoting Azulfidine En-tabs with PNU in the US. Coincidence?” It would not surprise me if we see another – and more significant – announcement concerning MOGN and PNU in the not too distant future. David